A multicentre randomiSed controlled TRial of Intravenous immunoglobulin (IVIg) versus standard therapy for the treatment of transverse myelitis in adults and children

Trial Profile

A multicentre randomiSed controlled TRial of Intravenous immunoglobulin (IVIg) versus standard therapy for the treatment of transverse myelitis in adults and children

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Immunoglobulin G (Primary) ; Methylprednisolone
  • Indications Myelitis
  • Focus Therapeutic Use
  • Acronyms STRIVE
  • Most Recent Events

    • 11 May 2017 This trial has been completed in the United Kingdom (end date: 11 May 2016).
    • 18 Jul 2016 Status changed from completed to discontinued.
    • 12 Jul 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top